Evidence map›Paper›PMID 39023313›Full record

ArticleJournal of medicinal chemistry2024

Discovery of Two Highly Selective Structurally Orthogonal Chemical Probes for Activin Receptor-like Kinases 1 and 2.

Václav Němec, Marek Remeš, Petr Beňovský, Michael C Böck, Eliška Šranková, Jong Fu Wong, Julien Cros, Eleanor Williams, Lap Hang Tse, David Smil and 19 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Václav NěmecInstitute for Pharmaceutical Chemistry, Structural Genomics Consortium, Johann Wolfgang Goethe-University, Max-von-Laue-Strasse 9, Frankfurt am Main, 60438, Germany.ORCID 0000-0001-6900-1368
Marek RemešDepartment of Chemistry, Masaryk University, Brno 625 00, Czech Republic.ORCID 0000-0003-3462-7517
Petr BeňovskýDepartment of Chemistry, Masaryk University, Brno 625 00, Czech Republic.
Michael C BöckDepartment of Chemistry, Masaryk University, Brno 625 00, Czech Republic.
Eliška ŠrankováDepartment of Chemistry, Masaryk University, Brno 625 00, Czech Republic.
Jong Fu WongCentre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7FZ, U.K.
Julien CrosCentre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7FZ, U.K.ORCID 0000-0003-3922-3036
Eleanor WilliamsCentre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7FZ, U.K.
Lap Hang TseCentre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7FZ, U.K.ORCID 0000-0002-5468-4626
David SmilDrug Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, Toronto, Ontario M5G 0A3, Canada.ORCID 0000-0002-6232-6087
Deeba EnsanDrug Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, Toronto, Ontario M5G 0A3, Canada.
Methvin B IsaacDrug Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, Toronto, Ontario M5G 0A3, Canada.ORCID 0000-0001-6424-5523
Rima Al-AwarDrug Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, Toronto, Ontario M5G 0A3, Canada.
Regina GomolkováDepartment of Biology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
Vlad-Constantin UrsachiDepartment of Biology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
Bohumil FafílekDepartment of Biology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
Zuzana KahounováInstitute of Biophysics of the Czech Academy of Sciences, Královopolská 135, 612 00 Brno Czech Republic.
Ráchel VíchováInstitute of Biophysics of the Czech Academy of Sciences, Královopolská 135, 612 00 Brno Czech Republic.
Ondřej VacekInternational Clinical Research Center, St. Anne's University Hospital, 602 00 Brno, Czech Republic.
Benedict-Tilman BergerInstitute for Pharmaceutical Chemistry, Structural Genomics Consortium, Johann Wolfgang Goethe-University, Max-von-Laue-Strasse 9, Frankfurt am Main, 60438, Germany.ORCID 0000-0002-3314-2617
Carrow I WellsStructural Genomics Consortium, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Cesear R CoronaPromega Corporation, Madison, Wisconsin 53716, United States.
James D VastaPromega Corporation, Madison, Wisconsin 53716, United States.
Matthew B RobersPromega Corporation, Madison, Wisconsin 53716, United States.
Pavel KrejciDepartment of Biology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
Karel SoučekInternational Clinical Research Center, St. Anne's University Hospital, 602 00 Brno, Czech Republic.
Alex N BullockCentre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7FZ, U.K.ORCID 0000-0001-6757-0436
Stefan KnappInstitute for Pharmaceutical Chemistry, Structural Genomics Consortium, Johann Wolfgang Goethe-University, Max-von-Laue-Strasse 9, Frankfurt am Main, 60438, Germany.ORCID 0000-0001-5995-6494
Kamil ParuchDepartment of Chemistry, Masaryk University, Brno 625 00, Czech Republic.ORCID 0000-0001-9502-3173

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Activin receptor-like kinases 1-7 (ALK1-7) regulate a complex network of SMAD-independent as well as SMAD-dependent signaling pathways. One of the widely used inhibitors for functional investigations of these processes, in particular for bone morphogenetic protein (BMP) signaling, is

Indexed as

Activin Receptors, Type IIActivin Receptors, Type IAnimalsBone Morphogenetic ProteinsDrug DiscoveryHumansMiceMolecular ProbesProtein Kinase InhibitorsPyrazolesSignal TransductionStructure-Activity RelationshipActivin Receptors, Type IActivin Receptors, Type IIBone Morphogenetic ProteinsMolecular ProbesProtein Kinase InhibitorsPyrazoles

Identifiers

PMID39023313
PMCPMC11320582

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.